Investigational Therapy Shows Promise For Treating AD

03/13/2018
shot

The investigational therapy ASN002, a novel janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor, effectively and safely treated patients with moderate to severe atopic dermatitis (AD), according to a recent study presented during the “Late Breaking Research” session at the 2018 American Academy of Dermatology Annual Meeting.

The 4-week phase 1b trial included participants with moderate to severe AD randomized to either once daily 20 mg, 40 mg, or 80 mg of ASN002 or placebo (n=36). Participants were not allowed to use topical corticosteroids or other immunosuppressants during the study. Using the Eczema Area and Severity Index (EASI), body surface area (BAS) and Investigator’s Global Assessment (IGA), the researchers assessed the efficacy of ASN002, as well as pharmacokinetic measurements, safety, and tolerability.
_________________________________________________________________________
RELATED CONTENT
Promising Data Presented on Investigational Therapy in Atopic Dermatitis
Biologic May Be Effective For Patients With AD and Asthma
_________________________________________________________________________
Overall, ASN002 was well-tolerated at all dosage levels and adverse events were mostly restricted to the first day of dosing, which included mild headache and nausea.

Participants who received ASN002 experienced rapid declines in EASI 50 and EASI 75 after 4 weeks of treatment, with an average decrease in EASI scores of 28% to 68% and an average decrease in Numeric Rating Scale scores of 19% to 51% after 4 weeks of treatment. In addition, participants who received 40 mg and 80 mg of ASN002 experienced improvements in BSA and IGA.

“This is the first clinical report on safety and efficacy of oral JAK/SKY inhibitor ASN002 in moderate to severe AD. ASN002 was very well tolerated and demonstrated robust activity in EASI and pruritus improvements after 4 weeks,” the researchers concluded.

—Melissa Weiss

Reference

Bissonnette R, Maari C, Forman S, et al. Efficacy and safety of oral ASN002, a novel JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled clinical study. Presented at: American Academy of Dermatology Annual Meeting; February 16-20, 2018; San Diego, CA.